ω-3 Fatty acids for major depressive disorder in adults: an abridged Cochrane review. by Appleton, Katherine et al.
ω-3 Fatty acids for major depressive
disorder in adults: an abridged
Cochrane review
Katherine M Appleton,1 Hannah M Sallis,2,3 Rachel Perry,4,5 Andrew R Ness,4,5
Rachel Churchill2
To cite: Appleton KM,
Sallis HM, Perry R, et al.
ω-3 Fatty acids for major
depressive disorder in adults:
an abridged Cochrane review.
BMJ Open 2016;6:e010172.
doi:10.1136/bmjopen-2015-
010172
▸ Prepublication history for
this paper is available online.
To view these files please
visit the journal online
(http://dx.doi.org/10.1136/
bmjopen-2015-010172).
Received 2 October 2015
Accepted 21 January 2016
1Department of Psychology,
Faculty of Science and
Technology, Bournemouth
University, Poole, UK
2Centre for Academic Mental
Health, School of Social and
Community Medicine,
University of Bristol, Bristol, UK
3MRC Integrative
Epidemiology Unit, School of
Social and Community
Medicine, University of
Bristol, Bristol, UK
4National Institute for Health
Research (NIHR) Biomedical
Research Unit in Nutrition,
Diet and Lifestyle at the
University Hospitals Bristol
NHS Foundation Trust and
the University of Bristol,
Bristol, UK
5School of Oral and Dental
Sciences, University of
Bristol, Bristol, UK
Correspondence to
Dr Katherine M Appleton;
k.appleton@bournemouth.ac.
uk
ABSTRACT
Objective: To assess the effects of n-3
polyunsaturated fatty acids (n-3PUFAs; also known as
ω-3 fatty acids) compared with comparator for major
depressive disorder (MDD) in adults.
Design: Systematic review and meta-analyses.
Data sources: The Cochrane Depression, Anxiety and
Neurosis Review Group’s Specialised Registers
(CCDANCTR) and International Trial Registries searched
to May 2015. CINAHL searched to September 2013.
Trial selection: Inclusion criteria: a randomised
controlled trial (RCT); that provided n-3PUFAs as an
intervention; used a comparator; measured depressive
symptomology as an outcome; and was conducted in
adults with MDD.
Outcomes: Primary outcomes were depressive
symptomology and adverse events.
Results: 20 trials encompassing 26 relevant studies
were found. For n-3PUFAs versus placebo, n-3PUFA
supplementation resulted in a small-to-modest benefit
for depressive symptomology: SMD=−0.32 (95% CI
−0.52 to −0.12; 25 studies, 1373 participants, very
low-quality evidence), but this effect is unlikely to be
clinically meaningful, is very imprecise and, based on
funnel plot inspection, sensitivity analyses and
comparison with large well-conducted trials, is likely to
be biased. Considerable evidence of heterogeneity
between studies was also found, and was not
explained by subgroup or sensitivity analyses.
Numbers of individuals experiencing adverse events
were similar in intervention and placebo groups
(OR=1.24, 95% CI 0.95 to 1.62; 19 studies, 1207
participants; very low-quality evidence). For n-3PUFAs
versus antidepressants, no differences were found
between treatments in depressive symptomology
(MD=−0.70 (95% CI −5.88 to 4.48); 1 study,
40 participants, very low-quality evidence).
Conclusions: At present, we do not have sufficient
evidence to determine the effects of n-3PUFAs as a
treatment for MDD. Further research in the form of
adequately powered RCTs is needed.
BACKGROUND
Major depressive disorder (MDD) is charac-
terised by: depressed mood or markedly
diminished pleasure or interest in all activities
for a consecutive period of 2 weeks, plus the
presence of four or more other symptoms;
signiﬁcant distress or impairment in function-
ing as a result of the symptoms; and an inabil-
ity to attribute symptoms to the physiological
effects of a substance or another medical con-
dition.1 Highly debilitating, difﬁcult to treat,
with a high rate of recurrence, and with
resultant negative impacts for both the indi-
vidual and for society,1 MDD is increasing in
prevalence and impact in terms of
disability-adjusted life years.2
One emerging potential treatment for
MDD is n-3 polyunsaturated fatty acids
(n-3PUFAs), also known as ω-3 fatty acids.
n-3PUFAs are a family of PUFAs, named as
such because of the positioning of the ﬁrst
double carbon bond on the third atom from
the methyl end of the acyl chain.3 4 All
members of the family are derived from
parent fatty acid 18:3n-3 (α-linolenic acid
(ALA)), via desaturation and elongation.
ALA, however, cannot be synthesised by
humans, and thus must be obtained from
the diet.3 4 Longer chain n-3PUFAs can be
formed in humans, but biological conversion
is slow and inefﬁcient, making diet an
important source of these fatty acids as well.5
Dietary sources of ALA include certain nuts
and seeds, such as walnuts, ﬂaxseed and
rapeseed oil. Dietary sources of the longer
Strengths and limitations of this study
▪ This review is systematic, and was conducted
following Cochrane guidelines.
▪ All included trials are directly relevant to our
research question.
▪ The data available to answer our research ques-
tion are currently very limited, of low quality and
likely to be biased.
▪ Our findings are imprecise and likely to be
biased.
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n-3PUFAs eicosapentaenoic acid (EPA) and docosahex-
aenoic acid (DHA) include fatty ﬁsh, some white ﬁsh,
shellﬁsh and other seafood, and certain animal products
dependent on the animal’s diet.4 6 7
Early work investigating population consumption
levels of n-3PUFAs and n-3PUFA-rich foods suggested
links with population levels of depressive conditions.8
Repeated studies since have also found similar associa-
tions. Within countries, n-3PUFA intakes have been
negatively associated with depressive symptoms.9 10 In
clinical studies, low levels of n-3PUFAs have been found
in individuals diagnosed with MDD, compared with con-
trols,11 12 and continuous relationships between
n-3PUFA status and depressive symptoms have also been
found.11 In randomised controlled trials (RCTs), beneﬁ-
cial effects of supplementation with n-3PUFAs compared
with placebo have been reported for MDD13 14 and for
other depressive disorders.15 16
Not all studies, however, report beneﬁcial effects.
Cross-sectional studies also report no associations
between n-3PUFA consumption and depressive symp-
toms,17 18 or associations explained entirely by confoun-
ders.19 Clinical studies report no associations between
n-3PUFA levels and depressive symptoms,20–22 and RCTs
report no beneﬁt compared with placebo in individuals
suffering from MDD23 24 and other depressive
conditions.25 26
Reviews and meta-analyses clearly demonstrate variabil-
ity between studies.27–31 Meta-analyses reveal some
beneﬁt of n-3PUFAs for depressive disorders,29 30 but
investigations of the heterogeneity also suggest differen-
tial effects of n-3PUFAs dependent on severity of depres-
sive symptoms at baseline.29 Sensitivity analyses suggest
no beneﬁts of n-3PUFAs for individuals with mild depres-
sive symptoms, but provide some suggestion of beneﬁt in
individuals with severe depressive symptoms.29 These
ﬁndings suggest a possible beneﬁt of n-3PUFAs for MDD.
Other reviews investigating a role for n-3PUFAs in
depressive disorders have recently been conducted.32–35
These reviews typically use a broad deﬁnition of depres-
sion to include a variety of depressive disorders and con-
ditions, in a number of populations, including children.
This review considers solely major or unipolar depressive
disorder, and focuses on adults.
Objective
To assess the effects of n-3PUFAs compared with com-
parator (eg, placebo, antidepressant treatment, standard
care) for MDD in adults.
METHODS
Our review was conducted as a Cochrane review,36 and
followed the methods set out in our protocol.37
Study inclusion
Only RCTs were included. Trials were included if they
involved adults, regardless of participant demographics
(eg, gender, age, country of residence), but we only
included trials that enrolled participants with a primary
diagnosis of major or unipolar depressive disorder from
a trained professional or a validated rating scale, or trials
that included a subgroup of these individuals. If a sub-
group was used, only the data from the subgroup were
included in the review, and only if the subgroup was
deﬁned and distinguished prior to randomisation. If
data from diagnosed and non-diagnosed individuals
were mixed, these trials were not included. Trials that
enrolled participants without MDD, but with another
primary psychiatric diagnosis were not included. We also
excluded trials that described a diagnosis of MDD that
was given only during or in relation to pregnancy. Trials
were only included in the review if we were certain that
all data were gained from participants with MDD. Trials
were included regardless of the presence of other
comorbid conditions, and regardless of participant use
of adjunct therapy for depression. Trials were included if
they used an exposure of n-3PUFAs as a sole or as an
adjunctive therapy, regardless of the source of n-3PUFA
provided, the dose, the mode of provision or duration of
supplementation; and if they included a comparator,
regardless of the comparator used (eg, placebo, anti-
depressant treatment, standard care). Our primary out-
comes were: (1) depressive symptomology, assessed
using any continuous validated measure of depressive
symptomology; and (2) adverse events, assessed using
number of individuals experiencing adverse events, as
reported. Secondary outcomes of interest were: (3)
depressive symptomology remission or response; (4)
quality of life; and (5) failure to complete. Trials were
included regardless of whether they reported on all out-
comes. Measures of risk of bias were also recorded.
Search methods for identification of studies
Suitable trials for inclusion were identiﬁed by searching
the Cochrane Depression, Anxiety and Neurosis Review
Group’s Specialised Register (CCDANCTR), CINAHL
and International Trials Registers, using the search
terms (depress* or dysthymi* or “affective disorder*” or “affect-
ive symptom*” or “mood disorder*” or “mental health)” AND
(dha or docosahex* or eicosapent* or epa or “fatty acid*” or
*ﬁsh* or *linolenic* or *omega* or n-3 or w-3 or *PUFA* or
“cod liver oil”). There were no restrictions on date, lan-
guage or publication status. We also checked the refer-
ence lists of all included trials and relevant reviews, and
contacted authors of identiﬁed trials for information on
unpublished or ongoing work. Searches of CCDANCTR
and International Trial Registers were most recently con-
ducted in May 2015; searches of CINAHL were most
recently conducted in September 2013.
Data collection
Two review authors (HMS and RP) independently
screened all titles, abstracts and all potentially relevant
full-text reports to identify suitable trials for inclusion.
Disagreements were resolved through discussion or
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consultation with a third person (KMA). Multiple
reports of the same trials were collated, so that each trial
rather than each report was the unit of interest in the
review. Articles in foreign languages were obtained and
translated.
Study characteristics and outcome data were extracted
using a data collection form developed speciﬁcally for
this work, and piloted on two trials prior to use for all
others. Two review authors (HMS and KMA or RP)
extracted all relevant study characteristics and outcome
data. Discordances were resolved by independent
abstraction and then discussion with a third author (RP
or KMA, respectively). Corresponding authors were also
contacted directly for relevant information. Risk of bias
was assessed for each trial independently by three review
authors (KMA, HMS and RP) for each domain speciﬁed
in the Cochrane Handbook,38 using prespeciﬁed cri-
teria.36 Each potential source of bias was judged to be of
high, low or unclear risk. We resolved disagreements by
discussion.
Analysis
Analyses were undertaken in RevMan. Analyses were
undertaken per comparator to ensure combination of
like with like. We analysed continuous data (following
determination of similar direction where different scales
were used) as standardised mean difference (SMD) with
95% CIs, using intention-to-treat (ITT) data (based on
number randomised), where possible. The SMD for all
studies was calculated using Hedges’ adjusted g (a for-
mulation of effect size that includes an adjustment to
correct for small sample bias39). Dichotomous data were
collected in the form of N per intervention group, and
were analysed as ORs with 95% CI. Aggregated data, per
study, were used. Estimates were made using
random-effects models primarily, due to likely hetero-
geneity between studies.39–41 Fixed-effects models were
also applied as sensitivity analyses. Where trials used
multiple treatment groups, each treatment group was
treated as an independent study (we deﬁne study either
as an independent trial arm, where trials encompassed
multiple arms, or as a complete trial, where only one
experimental arm was involved). No trials involved indi-
viduals in more than one treatment/comparison group.
Where the same comparator was used for all treatment
groups, data from comparison groups were split across
treatment groups, as equally as possible for analysis.
Multiple treatment groups were used to allow the use of
reported data (and so avoiding the use of pooling calcu-
lations) and to allow investigations of methodology
where possible. Where trials used multiple time points,
data from the longest follow-up period only were used
for analyses. We contacted investigators in order to verify
key trial characteristics and obtain missing numerical
outcome data where possible. SDs which remained
missing once authors had been contacted were imputed
from SD data from all other trials using the same
measure.42 Heterogeneity was investigated using
Higgins’ I2 statistic.43 44 Possible sources of heterogeneity
were identiﬁed a priori, to include publication bias, pres-
ence/absence of comorbid conditions, use of n-3PUFAs
as a sole/adjunct therapy and risk of bias. Publication
bias was investigated using funnel plot asymmetry.41
Subgroup analyses were conducted using subgroups of
studies to investigate effects due to the presence/
absence of comorbid conditions, and the use of
n-3PUFAs as a sole/adjunct therapy, using the same
methods as for the main analyses. The impact of risk of
bias was assessed using sensitivity analyses, which
included only the studies judged to be of low risk of (1)
selection bias; (2) performance bias; and (3) attrition
bias. Sensitivity analyses were also conducted to investi-
gate differences in study methodology that were identi-
ﬁed during the review process. Sensitivity analyses
included: (1) studies using a treatment composed solely
or predominantly of EPA; (2) studies using a placebo
not composed of ALA; (3) studies using ITT data; (4)
studies providing SDs; and (5) use of complete trials
(independent studies combined) where appropriate.
Results of all sensitivity analyses were compared with
those of our main analyses. The quality of evidence for
all outcomes was assessed using GRADE criteria, as
described by the Grades of Recommendation,
Assessment, Development and Evaluation Working
Group.38
RESULTS
Search results
Searches identiﬁed 677 records of potential relevance to
our review. Screening by title and abstract resulted in
the retrieval of 153 full-text papers, and of these, 85
records were found to relate to RCTs of relevance. Full
details of the search results are provided in ﬁgure 1. Of
the trials identiﬁed, Lucas et al45 involves individuals
both with and without MDD, and participants were
stratiﬁed by diagnosis for randomisation, thus we have
included only the subgroup of individuals with MDD.
The trial by Coryell46 includes tests of two doses of
n-3PUFA (1.14 and 2.28 g/day), the trial by da Silva
et al47 involves individuals who were randomised depend-
ent on antidepressant status (antidepressant use/no
antidepressant use) at trial entry, the trial by Jazayeri
et al48 involves two separate comparator groups
(placebo/antidepressant), the trial by Mischoulon et al49
includes tests of two interventions (enriched EPA/
enriched DHA), and the trial by Peet and Horrobin50
includes tests of three doses of n-3PUFA (1, 2 and 4 g/
day). In these ﬁve trials, all groups were independent,
thus we have considered each as a separate study. This
resulted in the inclusion in analyses of 26 independent
studies, involving a total of 1458 participants—Bot
et al,51 Carney et al,52 Coryell46 (1.14 g/day), Coryell46
(2.28 g/day), da Silva et al47 (AD), da Silva et al47 (nAD),
Gertsik et al,53 Gharekhani et al,54 Gonzalez et al,55
Grenyer et al,23 Jazayeri et al48 (placebo), Jazayeri et al48
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(AD), Lesperance et al,56 Lucas et al,45 Marangell et al,57
Mischoulon et al,58 Mischoulon et al49 (DHA),
Mischoulon et al49 (EPA), Nemets et al,13 Park et al,59
Peet and Horrobin50 (1 g/day), Peet and Horrobin50
(2 g/day), Peet and Horrobin50 (4 g/day), Rondanelli
et al,60 Silvers et al,24 Su et al.14
Included studies
Full characteristics of all 26 studies are provided in the
Cochrane publication.36 Brief details are given in table 1.
Studies varied in sample size (from n=546 (1.14 g/day)
to n=43256), although the majority of studies were small.
Only three trials49 52 56 included over 100 participants.
Trials were undertaken across the world, in clin-
ical14 23 48 49 52 54 58 59 and community settings.45 47 60
The majority of participants in all studies, but two52 54
were female (range 52% female51 to 100% female45 60).
Mean ages ranged from 2946 to 84 years.60 Five studies
included individuals with comorbidities,47 51 52 54 three
studies included individuals with no comorbidities,14 57 58
Figure 1 PRISMA diagram demonstrating the outcomes of the search process, and inclusion of studies in the review and
meta-analyses. CCDANCTR, Cochrane Depression, Anxiety and Neurosis Review Group’s Specialised Registers; MDD, major
depressive disorder; n-3PUFA, n-3 polyunsaturated fatty acid; RCT, randomised controlled trial.
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Table 1 Brief methodological details of all included studies
Study N Setting
Participants
(gender, age) Comorbidities
Adjunct
therapy
Intervention
(n-3PUFAs,
dose) Comparison* Duration
Depressive
symptomology
measure used
in analyses
Adverse
events
included in
analyses
Bot et al,
201051
25 Clinical, The
Netherlands
52% female, mean
age=54 years
✓ ✓ EPA—1 g/day Rapeseed oil
+medium
chain
triglycerides
12 weeks MADRS ✓
Carney et al,
200952
122 Clinical,
USA
34% female, mean
age=58 years
✓ ✓ EPA/DHA—
0.93/0.75 g/day
Corn oil 10 weeks HDRS (17 item) ✓
Coryell
unpublished
(1.14 g/day)46
11 (across
both studies)
Clinical/
community,
USA
82% female, mean
age=29 years
Possible ✓ EPA/DHA—
0.74/0.4 g/day
Oil 6 weeks MADRS ✓
Coryell
unpublished
(2.28 g/day)46
11 (across
both studies)
Clinical/
community,
USA
82% female, mean
age=29 years
Possible ✓ EPA/DHA—
1.48/0.8 g/day
Oil 6 weeks MADRS ✓
da Silva et al,
2005 (AD)47
31 (across
both studies)
Community,
Brazil
58% female, mean
age=64 years
✓ ✓ EPA/DHA—
0.72/0.48 g/day
Mineral oil 12 weeks MADRS ✓
da Silva et al,
2005 (nAD)47
31 (across
both studies)
Community,
Brazil
58% female, mean
age=64 years
✓ X EPA/DHA—
0.72/0.48 g/day
Mineral oil 12 weeks MADRS ✓
Gertsik et al,
201253
42 Clinical/
community,
USA
unknown gender
distribution, mean
age=41 years
Possible ✓ EPA/DHA/other
n-3PUFAs—
1.8/0.4/0.2 g/day
Olive oil 8 weeks HDRS (21 item) ✓
Gharekhani
et al, 201454
54 Clinical, Iran Completers—44%
female, mean
age=57 years
✓ X EPA/DHA—
1.08/0.72 g/day
Parrafin oil 16 weeks BDI ✓
Gonzalez
et al, 201155
20 Setting not
reported,
Venezuela
Completers—80%
female, mean
age=39 years
Possible ✓ EPA—3 g/day Not reported 8 weeks HDRS (17 item) X
Grenyer et al,
200723
83 Clinical,
Australia
61% female, mean
age=45 years
Possible Possible EPA/DHA—
0.56/2.2 g/day
Olive oil 16 weeks HDRS (17 item) ✓
Jazayeri et al
2008,
(placebo)48
60 (across
both studies)
Clincal, Iran Competers—69%
female, mean
age=35 years
Possible ✓ EPA—1 g/day Rapeseed oil 8 weeks HDRS (24 item) X
Jazayeri et al,
2008, (AD)48
60 (across
both studies)
Clincal, Iran Competers—69%
female, mean
age=35 years
Possible X EPA—1 g/day 20 mg
fluoxetine
8 weeks HDRS (24 item) X
Lesperance
et al, 201156
432 Clinical/
community,
Canada
69% female, mean
age=46 years
Possible Possible EPA/DHA—
1.05/0.15 g/day
Sunflower oil
plus 2% fish
oil
8 weeks MADRS ✓
Lucas et al,
200945
29 Community,
Canada
100% female,
mean
age=50 years
Possible X EPA/DHA—
1.05/0.15 g/day
Sunflower oil
plus 2% fish
oil
8 weeks HDRS (21 item) ✓
Continued
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Table 1 Continued
Study N Setting
Participants
(gender, age) Comorbidities
Adjunct
therapy
Intervention
(n-3PUFAs,
dose) Comparison* Duration
Depressive
symptomology
measure used
in analyses
Adverse
events
included in
analyses
Marangell
et al, 200357
36 Setting not
reported
Completers—80%
female, mean
age=47 years
X X DHA—2 g/day Not reported 6 weeks HDRS (28 item) X
Mischoulon
et al, 200958
41 Clinical,
USA
Completed one
postbaseline visit—
63% female, mean
age=43 years
X Possible EPA—1 g/day Parrafin oil 8 weeks HDRS (17 item) ✓
Mischoulon
et al, 2015
(DHA)49
196 (across
both studies)
Clinical,
USA
Completed one
postbaseline visit—
59% female, mean
age=46 years
Possible X EPA/DHA/other
n-3PUFAs—
0.18/0.9/
0.144 g/day
Soybean oil 8 weeks HDRS (17 item) ✓
Mischoulon
et al, 2015
(EPA)49
196 (across
both studies)
Clinical,
USA
Completed one
postbaseline visit—
59% female, mean
age=46 years
Possible X EPA/DHA/other
n-3PUFAs—
1.06/0.274/
0.102 g/day
Soybean oil 8 weeks HDRS (17 item) ✓
Nemets et al,
200213
20 Setting not
reported
85% female, mean
age=53 years
Possible Possible EPA—2 g/day Not reported 4 weeks HDRS (24 item) ✓
Park et al,
201559
35 Clinical,
Korea
77% female, mean
age=39 years
Possible ✓ EPA/DHA—
3.42/1.8 g/day
Safflower oil
plus oleic
acid
12 weeks HDRS (17 item) ✓
Peet and
Horrobin, 2002
(1 g/day)50
70 (across
three studies)
Clinical/
community,
UK
Gender distribution
unknown, mean
age=45 years
Possible ✓ EPA—1 g/day Parrafin oil 12 weeks HDRS (17 item) ✓
Peet and
Horrobin, 2002
(2 g/day)50
70 (across
three studies)
Clinical/
community,
UK
Gender distribution
unknown, mean
age=45 years
Possible ✓ EPA—2 g/day Parrafin oil 12 weeks HDRS (17 item) ✓
Peet and
Horrobin, 2002
(4 g/day)50
70 (across
three studies)
Clinical/
community,
UK
Gender distribution
unknown, mean
age=45 years
Possible ✓ EPA—4 g/day Parrafin oil 12 weeks HDRS (17 item) ✓
Rondanelli
et al, 201060
46 Nursing
home, Italy
100% female,
mean
age=84 years
Possible Possible EPA/DHA/other
n-3PUFAs—
1.67/0.83/
0.63 g/day
Parrafin oil 8 weeks GDS ✓
Silvers et al,
200524
77 Clinical/
community,
New
Zealand
53% female, mean
age=39 years
Possible Possible EPA/DHA—
0.6/2.4 g/day
Olive oil 12 weeks HDRS-SF
(12 item)
✓
Continued
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while all other studies included a mix. Twelve
studies included individuals who were all receiving
adjunct therapy at the time of the trial,46 47 (AD),48
(placebo),50–53 55 59 seven studies included individuals
who were all not receiving adjunct therapy,45 47 (nAD),48
(AD),49 54 57 and seven studies included a
mix.13 14 23 24 56 58 60 Studies used either an EPA only inter-
vention,13 48 50 51 55 58 a DHA only intervention,57 EPA/
DHA combinations14 23 24 45–47 52 54 56 59 and EPA/DHA/
other n-3PUFA combinations.49 53 60 Doses of n-3PUFAs
ranged from 148 50 (1 g/day),51 58 to 6.6 g/day.14 All
studies used a placebo comparator, with the exception of
one study that compared n-3PUFAs with antidepressants.48
(AD) A variety of placebo comparators were used, includ-
ing olive oil14 23 24 53 and parafﬁn oil.50 54 58 60 In the study
where n-3PUFAs were compared with antidepressants,
n-3PUFAs were given using EPA only at a dose of 1 g/day,
and compared with 20 mg/day ﬂuoxetine.48 (AD)
Treatment duration for each study ranged from 413 to 16
weeks.23 54 Depressive symptomology was reported using
continuous data61–64 in all studies. Number of individuals
experiencing adverse events were reported in 22
studies.13 14 23 24 45–47 49–54 56 58–60 Risk of bias was judged
to be very variable between studies. A graphical representa-
tion of all judgements is given in ﬁgure 2. Full details are
provided in the Cochrane publication.36
Our searches also identiﬁed 1 trial registration that
has been classiﬁed as an excluded study,38 9 RCTs that
are currently awaiting classiﬁcation and 16 RCTs that are
currently ongoing that may be suitable for future
reviews.36
Effects of interventions
Comparison of n-3PUFAs with placebo
Twenty-ﬁve studies involving 1438 individuals13 14 23 24
45–47 48 (placebo),49–60 compared n-3PUFAs with
placebo.
Depressive symptomology was lower after n-3PUFAs
compared with placebo: SMD=−0.32 (95% CI −0.52 to
−0.12), 25 studies, 1373 participants (see ﬁgure 3), but
effect sizes are small-to-modest, CIs range between a very
small (non-clinically beneﬁcial) to a modest (clinically
relevant) effect; there was substantial heterogeneity
between studies (I2=59%), and using GRADE criteria,
the quality of the evidence was judged to be very low.
A SMD of 0.32 represents a difference between groups
in scores on the Hamilton Depression Rating Scale
(HDRS; 17 items) of approximately 2.2 (0.8 to 3.6 (95%
CI)) points (based on the SDs reported in the trials
included).
Number of individuals experiencing adverse events
were similar in n-3PUFA and placebo groups—OR=1.24
(95% CI 0.95 to 1.62), 19 studies, 1207 participants
(see ﬁgure 4). CIs however are wide, and suggest that
effects could range from a reduction in odds of having
an adverse event of 5% to an increase of 62% in
n-3PUFA groups compared with placebo. Using
GRADE criteria, the quality of the evidence was judged
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to be very low, but there was no evidence of heterogen-
eity between studies (I2=0%). Adverse events were pre-
dominantly gastrointestinal in nature, but psychological
and other physical adverse events were also reported.
Analyses on secondary outcomes are reported in our
Cochrane publication.36
Reporting bias
The funnel plots for the analyses on our two primary
outcomes are presented in ﬁgures 5 and 6. These plots
demonstrate some asymmetry, suggesting possible publi-
cation bias in these outcomes.
Subgroup analyses
There was a statistically signiﬁcant difference for depres-
sive symptomology between subgroups based on pres-
ence/absence/possible comorbidities (χ2=7.23, df=2,
p=0.03), but the evidence of heterogeneity between sub-
groups was high (I2=72%), and effects were not clear.
There was no statistically signiﬁcant difference between
subgroups for adverse events (χ2=0.77, df=2, p=0.68),
and no evidence of heterogeneity between subgroups
(I2=0%). For subgroups based on presence/absence/
possible use of adjunct therapy, there was no statistically
signiﬁcant difference between subgroups for depressive
symptomology (χ2=1.01, df=2, p=0.60, I2=0%), or for
adverse events (χ2=2.92, df=2, p=0.23, I2=32%).
Sensitivity analyses
Using ﬁxed-effects models, results are similar to those
achieved using random-effects models (depressive symp-
tomology: SMD=−0.20 (95% CI −0.31 to −0.09); adverse
events: OR=1.29 (95% CI 0.99 to 1.67)), although effect
sizes were smaller. Effect size estimates in depressive
symptomology are half the size using ﬁxed-effects
models compared with using random-effects models.
Fourteen studies were judged to be of low risk of selec-
tion bias,13 14 23 24 45 49–51 56 58–60 six studies were
judged to be of low risk of performance
bias13 24 45 51 56 60 and seven studies were judged to be
of low risk of attrition bias.13 14 45 46 52 58 60 Analyses of
these sets of studies demonstrate no statistical differ-
ences between n-3PUFA and placebo groups in depres-
sive symptomology (SMD=−0.21 (95% CI −0.45 to 0.03);
SMD=−0.14 (95% CI −0.55 to 0.26); SMD=−0.39 (95%
CI −0.96 to 0.17), respectively), or in adverse events
(OR=1.31 (95% CI 0.98 to 1.75); OR=1.22 (95% CI 0.85
to 1.74); OR=0.82 (95% CI 0.46 to 1.45), respectively).
CIs, however, are wide and suggest both a possible clinic-
ally signiﬁcant beneﬁt of n-3PUFAs and a possible negli-
gible effect compared with placebo in depressive
symptomology, and a possible range of effects for
n-3PUFAs in adverse events from a small reduction to a
large increase, compared with placebo.
Additional sensitivity analyses
Eight studies used an intervention composed solely of
EPA.13 48 (placebo),50 (1 g/day),50 (2 g/day),50 (4 g/
day),51 55 58 Thirteen studies used an intervention com-
posed predominantly of EPA.14 45 46 (1 g/day),46 (2 g/
day),47 (AD),47 (nAD),49 (EPA),52–54 56 59 60 Nineteen
studies did not use a placebo containing
ALA.13 14 23 24 45 47 (AD),47 (nAD),50 (1 g/day),50 (2 g/
day),50 (4 g/day),52–60 Analyses of these sets of studies
demonstrated a modest beneﬁt of n-3PUFAs compared
with placebo for depressive symptomology (SMD=−0.45
(95% CI −0.74 to −0.15); SMD=−0.40 (95% CI −0.72 to
−0.08); SMD=−0.40 (95% CI −0.62 to −0.15),
Figure 2 Judgements of risk of bias for each domain and
each study in the review.
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respectively) and no differences between groups for
adverse events (OR=0.99 (95% CI 0.39 to 2.45);
OR=1.26 (95% CI 0.88 to 1.80); OR=1.14 (95% CI 0.85
to 1.54), respectively). CIs for all analyses, however, are
again wide and suggest an effect size estimate for depres-
sive symptomology that ranges from small to clinically
signiﬁcant, and both a possible reduction and an
increase in adverse events. The overall effect size
estimate for depressive symptomology was larger in these
analyses than in our main analyses, but the evidence of
heterogeneity between studies was also higher, except in
the analyses on studies using an intervention that was
solely EPA (I2=0%).
Analyses of only the studies for which we had ITT
data,13 14 23 45 46 48 (placebo)52–54 56 58 60 of only the
studies that provided SDs,13 14 23 24 45–48 (placebo)51–60
Figure 3 Forest plot for the outcome depressive symptomology (continuous) for the comparison of n-3PUFAs with placebo.
DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; n-3PUFA, n-3 polyunsaturated fatty acid.
Figure 4 Forest plot for the outcome adverse events for the comparison of n-3PUFAs with placebo. DHA, docosahexaenoic
acid; EPA, eicosapentaenoic acid; n-3PUFA, n-3 polyunsaturated fatty acid.
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and using combined studies where appropriate, reveal
ﬁndings that are very comparable to those achieved in
our main analyses.
Comparison of n-3PUFAs with antidepressants
Data were only available from one study (40 partici-
pants)48 (AD) for this comparison. Depressive sympto-
mology, based on the HDRS, was similar in n-3PUFA
and antidepressant groups: MD=−0.70 (95% CI −5.88 to
4.48), but CIs include a possible modest beneﬁt and a
possible modest detriment of n-3PUFAs compared with
antidepressants. Adverse events were reported only as
number of events experienced as opposed to number of
individuals experiencing at least one event, so could not
be analysed.
DISCUSSION
Summary of main results
Studies were found comparing the impact of n-3PUFAs
for MDD to placebo (25 studies, involving 1438 partici-
pants), and to antidepressant treatment (1 study involv-
ing 40 participants). For the placebo comparison, there
was a small-to-modest beneﬁcial effect of n-3PUFAs on
depressive symptomology, compared with placebo (the
equivalent of approximately 2.2 (95% CI 0.8 to 3.6)
HDRS points). National Institute for Health and Care
Excellence (NICE)65 has previously suggested a reduc-
tion in HDRS score of three points or more to demon-
strate clinical signiﬁcance, thus the clinical signiﬁcance
of the effect from this meta-analysis is small. Our CIs do
not exclude a clinically meaningful effect, but also
include a negligible effect at the lower end. Numbers of
individuals experiencing adverse events were similar
between intervention and placebo groups, although
wide CIs suggest that effects could range from a small
reduction to a modest increase in n-3PUFA groups com-
pared with placebo. For the comparison with antidepres-
sants, no differences between treatment with n-3PUFAs
and treatment with antidepressants were found in
depressive symptomology.
The evidence available
The evidence for all outcomes for both comparisons was
judged to be low-to-very low using GRADE criteria. For
both comparisons and all outcomes, the evidence is
limited and highly heterogeneous, resulting in ﬁndings
that are imprecise and potentially biased. The evidence
available largely derives from few studies (n=26) and few
participants (N=1458). All studies were directly relevant
to our research question, but considerable differences
were identiﬁed in all aspects of study methodology, and
the majority of available studies were small. Almost half
of all participants in our analyses derive from only three
trials,49 52 56 and even using random-effects models, the
contribution of these three trials to our overall estimates
is high. While these trials were judged to be of low risk
of bias on most measures, biases or methodological-
speciﬁc outcomes in these trials may have contributed to
our overall result. Our funnel plots also suggest an
absence of small studies showing null ﬁndings, and sen-
sitivity analyses using ﬁxed-effects models suggest a posi-
tive inﬂuence from small positive studies in our main
analyses. These ﬁndings suggest that our overall effect
size estimates may be biased towards a positive ﬁnding
for n-3PUFAs compared with the reality. Sensitivity ana-
lyses using only the studies that were judged to be of low
risk of bias also suggest bias in our main analyses on
depressive symptomology, towards a positive ﬁnding for
n-3PUFAs. These analyses report smaller effect sizes than
those found in our main analyses, and CIs include the
possibility of no differences between groups. This evi-
dence, alongside that of the funnel plots and the ﬁnd-
ings using ﬁxed-effects models suggest that the true
effect of n-3PUFAs is likely to be smaller than that
reported in our main analyses. Imprecise effect size esti-
mates were found for all outcomes. In all analyses, pos-
sible effects range from negligible effects to important
clinical beneﬁts. While this imprecision does not rule
out clinically relevant effects, considerable caution must
be used in interpreting all effect size estimates, and
further evidence, in the form of adequately powered
Figure 5 Funnel plot for the outcome depressive
symptomology (continuous) for the comparison of n-3
polyunsaturated fatty acids with placebo.
Figure 6 Funnel plot for the outcome adverse events for the
comparison of n-3 polyunsaturated fatty acids with placebo.
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well-designed trials, is clearly required before ﬁrm con-
clusions can be drawn. Findings in our primary outcome
of depressive symptomology also demonstrate consider-
able evidence of heterogeneity. This heterogeneity was
not explained by prespeciﬁed subgroups, nor by consid-
eration of study methodology or our decisions for ana-
lyses. An effect based on the sole use of EPA may be
suggested, but the evidence is very limited. Further work
is again required. For the comparison with antidepres-
sant treatment, only one small study was available, and
this study was given judgements of high risk of bias in
many domains. Inconsistency in trial reporting for both
comparisons was obvious.
Strengths and weaknesses of the review
The ﬁndings of this review may be biased due to the
bias in the evidence available—only a limited number of
studies were available for assessing outcomes for either
comparison, and there was a high relative weighting in
all analyses for the placebo comparison from three trials
of high quality. The review process also may have been
biased. Our searches were more likely to detect articles
published in English and in mainstream journals. We
were also unable to contact authors of some articles that
may have been relevant. Reliance on available data also
meant that only limited studies could contribute to
certain analyses. We did not attempt to gain
participant-level data from study authors, nor did we
attempt more complex analyses than those detailed. We
relied on authors of existing relevant studies or trial
registrations to also inform us of unpublished studies.
Our searches covered relevant conference-based publica-
tions, but we made no further attempts to ﬁnd or iden-
tify unpublished literature.
Agreements and disagreements with other reviews
Many published reviews and meta-analyses investigating
a role for n-3PUFAs for depression compared with
placebo are available.27–35 Many of these reviews focus
also on RCTs, but typically use a broader deﬁnition of
depressive disorder, and the relevance of some studies
included in these reviews has been debated.66 These
published reviews largely provide a combined estimate
that is similar to that achieved in our analyses, although
our interpretation is more conservative, through consid-
eration of clinical signiﬁcance and possible effects
demonstrated by CIs. All reviews are based on the same
very limited pool of studies, and report substantial het-
erogeneity between studies and high probability of bias.
Interestingly, our effect size estimates are also compar-
able to some degree to those suggested by recent
meta-analyses on the effects of antidepressants for MDD,
compared with placebo.67–69 CIs, however, suggest more
precise small-to-modest effects for antidepressants, while
our CIs suggest an effect that may range from negligible
to modest.
CONCLUSIONS
At present, we do not have sufﬁcient good quality evi-
dence to determine the effects of n-3PUFAs as a treat-
ment for MDD. Our primary analyses suggest a
small-to-modest, non-clinically relevant beneﬁt of
n-3PUFAs on depressive symptomology compared with
placebo, although the effect size estimate is imprecise,
and the quality of the evidence on which this result is
based is very low and highly biased. Sensitivity analyses,
funnel plot inspection and comparison of our results
with those of large well-conducted trials also suggest that
this effect size estimate is likely to be biased towards a
positive ﬁnding for n-3PUFAs, and that the true effect is
likely to be smaller. Our data do suggest similar rates of
adverse events in n-3PUFA and placebo groups,
although the evidence is again of very low quality. The
one study that directly compares n-3PUFAs with antide-
pressants in our review ﬁnds comparable beneﬁt, but
the quality of the evidence here is very low. Given the
high rates of adverse events associated with some antide-
pressants, n-3PUFAs may offer an alternative treatment
of possible beneﬁt and reduced side effects, but more
evidence regarding both the potential positive and nega-
tive effects of n-3PUFAs for MDD is required before
such a suggestion can be advocated.
More adequately powered, well-designed trials are
required to increase the evidence base, and explore
particularly the heterogeneity found between studies.
Trials that compare n-3PUFAs with usual antidepressant
treatment, and studies to investigate differing effects
dependent on individual characteristics and study meth-
odology are particularly important. Mechanistic studies
are also preferentially required, to identify the mechan-
isms both for the development and treatment of MDD,
and the possible actions in these pathways for
n-3PUFAs.
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